CClinicalTrials.gg
TerminatedNCT02574624VISIAUpdated Sep 26, 2017

Vitreous Surgery With Intraocular Assistance

An interventional study of Intraocular assistance in Traction Retinal Detachments, Rhegmatogenous Retinal Detachments and Dislocated Intraocular Lens, sponsored by Johns Hopkins University. Terminated at 1 site in United States. Open to participants aged 18 Years to 100 Years. Per ClinicalTrials.gov, last updated 2017-09-26.

Sponsored by Johns Hopkins University · Not applicable, Interventional, and Health services research

Why this study was terminated
Difficulty in finding patients with complex retinal pathology to enroll in this study.
Phase
Not applicable
Study type
Interventional
Enrollment
5
Allocation
Not applicable
Ages
18 Years to 100 Years
Sex
All
01

Study summary

To Assess the Safety of Vitreous surgery with intraocular assistance (VISIA) \& to identify and document with video evidence and surgeon's case report forms intraocular maneuvers that are facilitated by VISIA.

Read the detailed description

Standard care surgery will be done with a few novel additions to facilitate the surgical procedure. Currently 3 ports are inserted by creating holes in the sclera (white part of the eye) to enter into the posterior part of the eye. When complex dissection is needed, a fourth port will be inserted. The assistant will insert light source through the 4th port. This eliminates the need for the surgeon to hold the light in one hand. Hence allows freeing of both hands for the surgeon to use a forceps in one hand to grasp and elevate membranes and a scissors in the other to cut connections between the retina and the membranes. When membranes are particularly thick, it can be difficult to dissect with a single forceps holding up the membrane. In this situation, a 5th port will be inserted allowing the assistant to insert a light source through one and a forceps though another. The surgeon will have a forceps in one hand and a scissors in another making dissection process more efficient.

02

Conditions studied

  • Traction Retinal Detachments
  • Rhegmatogenous Retinal Detachments
  • Dislocated Intraocular Lens
03

In context

Retinal Detachment

207 studies on the registry are indexed under Retinal Detachment; 27 are open to participants now.

This study's enrollment of 5 is below the median of 50 across 136 interventional studies indexed under Retinal Detachment.

Browse Retinal Detachment studies →

Lead sponsor

Johns Hopkins University is the lead sponsor of 1,783 studies on the registry; 313 are open to participants now.

Of its 203 completed or terminated interventional studies of FDA-regulated products, 140 (69%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 100 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

All subjects must meet the following criteria to be eligible for study entry:

  • Signed informed consent and authorization of use and disclosure of protected health information
  • Age ≥18 years
  • Subject will have complex retinal pathology for which it is judged that surgical objectives could be facilitated by VISIA

Exclusion criteria

Exclusion Criteria:

Subjects who meet any of the following criteria will be ineligible for study entry:

  • Patients with disease processes such as macular pucker and macular hole that are generally well-managed by standard two-handed vitrectomy.
05

Study design

Phase
Not applicable
Primary purpose
Health services research
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
5 participants (actual)

Study arms

  • Experimental
    Intraocular Assistance

    Intraocular assistance in patients undergoing standard of care vitreous surgeries

    Procedure: Intraocular assistance

Interventions

  • ProcedureIntraocular assistance

    Intraocular assistance with help of surgical assistants during vitreous surgery (VISIA) in patients who require vitreous surgeries as part of standard of care procedure for conditions like retinal detachments, dislocated intraocular lens and glaucoma patients requiring endophotocoagulation.

06

What researchers measure

Primary outcomes

  1. The primary outcome measure is recording of adverse events directly related to VISIA and adverse events unrelated to VISIA.

    Time frame: 4 months

Secondary outcomes

  1. Surgeon's assessment of the benefits and risks of VISIA recorded on the surgical case report form.

    Time frame: 4 months

  2. Assistant's assessment of the benefits and risks of VISIA recorded on the surgical case report form.

    Time frame: 4 months

07

Study locations

1 site
  • Wilmer Eye Institute, Johns Hopkins University School of Medicine
    Baltimore, Maryland 21287, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Sep 26, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02574624
Lead sponsor
Johns Hopkins University
Responsible party
Peter A Campochiaro, MD (Professor of Ophthalmology and Neuroscience, Johns Hopkins University) — Principal investigator
First posted
Oct 14, 2015
Start date
Nov 2015
Primary completion
Sep 2017
Completion
Sep 2017
Last update
Sep 26, 2017

Study contacts

Peter A. Campochiaro, MD
principal investigator · Johns Hopkins University

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Sep 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion